Search results
Results from the WOW.Com Content Network
Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
The European Prospective Investigation into Cancer and Nutrition (EPIC) study is a Europe-wide prospective cohort study of the relationships between diet and cancer, as well as other chronic diseases, such as cardiovascular disease. With over half a million participants, it is the largest study of diet and disease to be undertaken.
Elacestrant was not McDonnell’s first attempt at bringing a breast cancer drug to market. In 1996, his lab developed a similar drug, etacstil, which was the first oral medication in this class ...
Such a test or clinical trial is called a placebo-controlled study, and its control is of the negative type. A study whose control is a previously tested treatment, rather than no treatment, is called a positive-control study, because its control is of the positive type. Government regulatory agencies approve new drugs only after tests ...
In terms of cancer prevention, a 2019 study found that participants with the highest intake of lutein and zeaxanthin had the lowest risk of colorectal cancer. Vitamin A Salmon is rich in vitamin A ...
A series of blister cavities is sometimes called a blister card or blister strip as well as blister pack. The difference between a strip pack and blister pack is that a strip pack does not have thermo-formed or cold formed cavities; the strip pack is formed around the tablet at a time when it is dropped to the sealing area between sealing moulds.
The women must be cancer-free upon enrolling in the study, which will follow them for 30 years to see how their medical histories, lifestyle factors and experiences of racism affect their risk of ...
(There was also an Acute Leukemia Group A, which later became the Children's Cancer Study Group. [1]) During this time, the group expanded to a national level. Holland became the new chairman in 1962 after Frei resigned. The group changed its name to Cancer and Leukemia Group B in 1976 to reflect its role with solid tumors as well as leukemia.